MedTrace Logo

PDGeneration: Mapping the Future of Parkinson's Disease

NCT04057794 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1982

Last updated 2023-07-14

No results posted yet for this study

Summary

To assess the feasibility, impact, and participant satisfaction of offering Clinical Laboratory Improvement Amendments (CLIA) certified genetic testing as part of clinical care for People with Parkinson's disease (PWP).

Conditions

  • Parkinson's Disease and Parkinsonism

Interventions

DEVICE

Lab Assay for seven genetic variants for Parkinson's Disease

Counseling provided to participant by site clinician/physician/genetic counselor.

DEVICE

Lab Assay for seven genetic variants for Parkinson's Disease

Counseling provided to participant by centralized genetic counseling group at Indiana University.

Sponsors & Collaborators

  • Fulgent Laboratories

    collaborator UNKNOWN

  • Indiana University

    collaborator OTHER

  • The Parkinson Study Group

    collaborator NETWORK

  • Navitas Clinical Research, Inc

    collaborator UNKNOWN

  • Parkinson's Foundation

    lead OTHER

Principal Investigators

  • Roy N Alcalay, MD, MS · Columbia University

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-15
Primary Completion
2021-12-01
Completion
2025-04-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04057794 on ClinicalTrials.gov